4:36 PM
 | 
Jul 12, 2013
 |  BC Extra  |  Company News

GSK drops COPD indication from Relvar Ellipta Japanese NDA

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) withdrew chronic obstructive pulmonary disease (COPD) as an indication on the Japanese NDA for Relvar Ellipta fluticasone furoate/vilanterol. The product -- a once-daily, fixed dose combination of the inhaled corticosteroid fluticasone furoate and a long-acting adrenergic receptor beta 2 agonist (LABA) vilanterol administered with the dry powder Ellipta inhaler -- is still under review for...

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >